{"id":"https://openalex.org/W2270699631","doi":"https://doi.org/10.1200/jco.2001.19.12.3018","title":"Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network","display_name":"Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network","publication_year":2001,"publication_date":"2001-06-15","ids":{"openalex":"https://openalex.org/W2270699631","doi":"https://doi.org/10.1200/jco.2001.19.12.3018","mag":"2270699631","pmid":"https://pubmed.ncbi.nlm.nih.gov/11408496"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2001.19.12.3018","doi":"https://doi.org/10.1200/jco.2001.19.12.3018","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2001.19.12.3018","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036076577","display_name":"Anthony A. Meluch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony A. Meluch","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073724595","display_name":"F. Anthony Greco","orcid":"https://orcid.org/0009-0009-4578-0630","observed_orcids":["https://orcid.org/0009-0009-4578-0630"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Anthony Greco","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard A. Burris","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110222461","display_name":"Timothy J. O\u2019Rourke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy O\u2019Rourke","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015013595","display_name":"Gregory L. Ortega","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory Ortega","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109361256","display_name":"Ronald G. Steis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald G. Steis","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031741135","display_name":"Lisa H. Morrissey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa H. Morrissey","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Valerie Johnson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Valerie Johnson","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Sarah Cannon Cancer Center, Nashville, TN; Tennessee Oncology, Professional Limited Liability Corporation, Grand Rapids Community Clinical Oncology Program, Grand Rapids, MI; Mid-Florida Hematology & Oncology Centers, Professional Association, Orange City, FL; and Atlanta Cancer Care, Atlanta, GA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":15.5587,"has_fulltext":false,"cited_by_count":208,"citation_normalized_percentile":{"value":0.99485276,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"19","issue":"12","first_page":"3018","last_page":"3024"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12695","display_name":"Urinary and Genital Oncology Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9879999756813049},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":1.0},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.9319999814033508},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7979999780654907},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7200000286102295},{"id":"https://openalex.org/keywords/platinum-refractory-disease","display_name":"platinum-refractory disease","score":0.843999981880188},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.7519999742507935},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9359999895095825},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.5979999899864197},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.8899999856948853}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8965442180633545},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.8501038551330566},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6616857051849365},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6052930951118469},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5835526585578918},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5603257417678833},{"id":"https://openalex.org/C2778065480","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Transitional cell carcinoma","level":4,"score":0.556482195854187},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.5444265007972717},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44954344630241394},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.44569021463394165},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.44365549087524414},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.41072767972946167},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.39993521571159363},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3517445921897888},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3422297239303589},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3217119574546814},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.32153719663619995}],"mesh":[{"descriptor_ui":"D000093542","descriptor_name":"Gemcitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000206","descriptor_name":"Actuarial Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002295","descriptor_name":"Carcinoma, Transitional Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002295","descriptor_name":"Carcinoma, Transitional Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019459","descriptor_name":"Urothelium","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2001.19.12.3018","doi":"https://doi.org/10.1200/jco.2001.19.12.3018","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2001.19.12.3018","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:11408496","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11408496","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W6664079","https://openalex.org/W23441172","https://openalex.org/W1534334787","https://openalex.org/W1786169419","https://openalex.org/W1820014750","https://openalex.org/W1840050571","https://openalex.org/W1855374361","https://openalex.org/W1862964936","https://openalex.org/W1893740135","https://openalex.org/W1939723756","https://openalex.org/W1941332786","https://openalex.org/W1957837469","https://openalex.org/W1968487988","https://openalex.org/W1979300931","https://openalex.org/W1988919112","https://openalex.org/W2008702837","https://openalex.org/W2014960675","https://openalex.org/W2016919073","https://openalex.org/W2067795764","https://openalex.org/W2090906593","https://openalex.org/W2098767932","https://openalex.org/W2101562875","https://openalex.org/W2123927174","https://openalex.org/W2240844634","https://openalex.org/W2268861790","https://openalex.org/W2417734794","https://openalex.org/W3041047318","https://openalex.org/W3135765092"],"related_works":["https://openalex.org/W1530228579","https://openalex.org/W1833688292","https://openalex.org/W2419565165","https://openalex.org/W2049701654","https://openalex.org/W2088495337","https://openalex.org/W2134054382","https://openalex.org/W2103133513","https://openalex.org/W1991893506","https://openalex.org/W2240844634","https://openalex.org/W102404514"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"evaluate":[2],"the":[3,21,135,208,220],"toxicity":[4,167],"and":[5,12,44,63,72,126,142,149,176,186,188,200,204,225,246],"efficacy":[6],"of":[7,20,95,118,154,198,213,219],"combination":[8,197],"chemotherapy":[9,161],"with":[10,16,29,51,159,215,229,254],"paclitaxel":[11,52,199],"gemcitabine":[13,64,201],"in":[14,207,243,252],"patients":[15,28,48,97,122,156,180,214,253],"advanced":[17,30,216],"transitional-cell":[18,217],"carcinoma":[19,33,218],"urothelial":[22,32,221],"tract.":[23,222],"PATIENTS":[24],"AND":[25],"METHODS:":[26],"Fifty-four":[27],"unresectable":[31],"entered":[34],"this":[35],"multi-centered,":[36],"community-based,":[37],"phase":[38,244],"II":[39,245],"trial":[40],"between":[41],"May":[42],"1997":[43],"December":[45],"1999.":[46],"All":[47],"were":[49,75,147],"treated":[50,158],"200":[53],"mg/m(2)":[54,66],"by":[55,232],"1-hour":[56],"intravenous":[57],"(IV)":[58],"infusion":[59],"on":[60,68],"day":[61],"1":[62],"1,000":[65],"IV":[67],"days":[69],"1,":[70],"8,":[71],"15;":[73],"courses":[74],"repeated":[76],"every":[77],"21":[78],"days.":[79],"Patients":[80],"who":[81],"had":[82,105,191],"objective":[83],"response":[84],"or":[85,210],"stable":[86],"disease":[87],"continued":[88],"treatment":[89,212],"for":[90,134,184],"six":[91],"courses.":[92],"RESULTS:":[93],"Twenty-nine":[94],"54":[96],"(54%;":[98],"95%":[99],"confidence":[100],"interval,":[101],"40%":[102],"to":[103,108,163],"67%)":[104],"major":[106],"responses":[107],"treatment,":[109],"including":[110,171],"7%":[111],"complete":[112],"responses.":[113],"With":[114],"a":[115],"median":[116,132],"follow-up":[117],"24":[119],"months,":[120],"16":[121],"(30%)":[123],"remain":[124],"alive":[125],"nine":[127],"(17%)":[128],"are":[129],"progression-free.":[130],"The":[131,196],"survival":[133,145],"entire":[136],"group":[137],"was":[138,168],"14.4":[139],"months;":[140],"1-":[141],"2-year":[143],"actuarial":[144],"rates":[146],"57%":[148],"25%,":[150],"respectively.":[151],"Seven":[152],"(47%)":[153],"15":[155],"previously":[157],"platinum-based":[160],"responded":[162],"paclitaxel/gemcitabine.":[164],"Grade":[165],"3/4":[166],"primarily":[169],"hematologic,":[170],"leukopenia":[172],"(46%),":[173],"thrombocytopenia":[174],"(13%),":[175],"anemia":[177],"(28%).":[178],"Ten":[179],"(19%)":[181],"required":[182],"hospitalization":[183],"neutropenia":[185],"fever,":[187],"one":[189],"patient":[190],"treatment-related":[192],"septic":[193],"death.":[194],"CONCLUSION:":[195],"is":[202],"active":[203],"well":[205,250],"tolerated":[206],"first-":[209],"second-line":[211],"Response":[223],"rate":[224],"duration":[226],"compare":[227],"favorably":[228],"those":[230],"produced":[231],"other":[233],"active,":[234],"first-line":[235],"regimens.":[236],"This":[237],"regimen":[238],"should":[239],"be":[240],"further":[241],"evaluated":[242],"III":[247],"studies,":[248],"as":[249,251],"compromised":[255],"renal":[256],"function.":[257]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}